Meeting NewsVideo

VIDEO: Oral AMD treatment meets phase 2 endpoints

CHICAGO — At the American Society of Retina Specialists meeting, Michael Stewart, MD, chairman and professor of ophthalmology at the Mayo Clinic of Jacksonville, Florida, discusses phase 2 results of AKST4290 (Alkahest), an orally administered small molecule CCR3 inhibitor.

CHICAGO — At the American Society of Retina Specialists meeting, Michael Stewart, MD, chairman and professor of ophthalmology at the Mayo Clinic of Jacksonville, Florida, discusses phase 2 results of AKST4290 (Alkahest), an orally administered small molecule CCR3 inhibitor.

    See more from ASRS 2019